Catherine Friedman, Alex Aravanis
Grail has appointed Catherine Friedman as chair of the firm's board of directors. Friedman succeeds Bill Rastetter, who will continue to serve as a director of the firm's board. Friedman joined the board in July 2017. She has also held numerous executive positions during her investment banking career with Morgan Stanley, including as managing director and head of West Coast healthcare, and co-head of the biotechnology practice. Friedman is also a board member at Altaba, Radius Health, and Lyell Immunopharma.
Grail has also appointed Alex Aravanis as CSO and head of R&D. Aravanis is a cofounder of Grail. Prior to being CSO, Aravanis served as VP of research and development. He previously served as senior director of R&D for Illumina. In addition, Aravanis served as VP of development and CSO of Sapphire Energy and was a cofounder and VP of engineering of Pria Diagnostics.